

# COVID-19 Vaccine Dosing Recommendations

## Primary Series

### Pfizer/BioNTech

**6 months-<5 years old:** 3 mcg IM at 0, 3, and ≥8 weeks after dose 2

**5-11 years old:** 10 mcg IM at 0 and 3 weeks

**≥12 years old:** 30 mcg IM at 0 and 3-8<sup>1</sup> weeks

(Immunocompromised<sup>2</sup> persons ≥5 years old: 3<sup>rd</sup> primary dose ≥4 weeks after the 2<sup>nd</sup>)

5 - <6 years old →

6 - 11 years old →

≥12 years old →

## Booster Dose<sup>1</sup>

One dose of Pfizer/BioNTech 10 mcg **BIVALENT**  
≥2 months after primary series or most recent monovalent booster

One dose of Pfizer/BioNTech 10 mcg **OR** Moderna 25 mcg **BIVALENT**  
≥2 months after primary series or most recent monovalent booster

One dose of Pfizer/BioNTech 30 mcg **OR** Moderna 50 mcg **BIVALENT**<sup>†</sup>  
≥2 months after primary series or most recent monovalent booster

One dose of Pfizer/BioNTech 10 mcg **BIVALENT**  
≥2 months after primary series or most recent monovalent booster

One dose of Pfizer/BioNTech 10 mcg **OR** Moderna 25 mcg **BIVALENT**  
≥2 months after primary series or most recent monovalent booster

One dose of Pfizer/BioNTech 30 mcg **OR** Moderna 50 mcg **BIVALENT**<sup>†</sup>  
≥2 months after primary series or most recent monovalent booster

One dose of Pfizer/BioNTech 30 mcg **OR** Moderna 50 mcg **BIVALENT**<sup>†</sup>  
≥2 months after primary series or most recent monovalent booster

### Moderna

**6 months-5 years old:** 25 mcg IM at 0 and 4 weeks

**6-11 years old:** 50 mcg IM at 0 and 4 weeks

**≥12 years old:** 100 mcg IM at 0 and 4-8<sup>2</sup> weeks

(Immunocompromised<sup>2</sup> persons: 3<sup>rd</sup> primary dose ≥4 weeks after the 2<sup>nd</sup>)

5 - <6 years old →

6 - 11 years old →

≥12 years old →

### Novavax

**≥12 years old:** 0.5 mL IM at 0 and 3 weeks

≥12 years old →

### Johnson & Johnson\*

≥18 years old: 0.5 mL (5x10<sup>10</sup> viral particles) IM once

(Immunocompromised<sup>2</sup> : 1 dose of mRNA vaccine ≥4 weeks after 1st J&J dose)

\*FDA limits use to only those who are unable or unwilling to receive an mRNA vaccine (Pfizer/BioNTech or Moderna) because of thrombosis with thrombocytopenia syndrome (TTS) risk

≥18 years old →

Pfizer/BioNTech 30 mcg **OR** Moderna 50 mcg **BIVALENT**<sup>†</sup>  
≥2 months after primary J&J immunization (≥2 months after mRNA dose in immunocompromised patients<sup>3</sup>) or most recent monovalent booster

### Bivalent Boosters

- CDC recommends use of bivalent boosters regardless of number of previous booster doses given
- Pfizer/BioNTech and Moderna bivalent booster doses contain mRNA components of the original virus and a common component of BA.4 and BA.5 (lineages of the Omicron variant)

### Novavax Monovalent Booster

† In persons ≥18 years old who have not previously received a COVID-19 booster vaccine dose and who are unable to receive an mRNA vaccine, a Novavax monovalent booster dose may be given ≥6 months after a primary series

1. An 8-week interval may be optimal for certain persons ≥12 years old, especially males 12-39 years old. A standard 3- (Pfizer/BioNTech) or 4- (Moderna) week interval between the first two doses should still be used in adults ≥65 years old, persons who are moderately or severely immunocompromised, and other persons who require more rapid protection because of high levels of community spread of SARS-CoV-2 infection or a high risk of severe COVID-19. See: <https://bit.ly/38i7CIH>.
2. Immunocompromised: active cancer treatment (solid tumors or hematologic), organ transplant, stem cell transplant within the last 2 years, moderate or severe primary immunodeficiency, advanced or untreated HIV infection, high-dose corticosteroids (≥ 20 mg prednisone/day or equivalent), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, severely immunosuppressive chemotherapy, TNF blockers, other immunosuppressive or immunomodulatory biologic agents.
3. In persons who received an initial J&J dose and already received a booster dose (Pfizer/BioNTech, Moderna [50 mcg, 0.25 ml], or J&J), without having had the 2<sup>nd</sup> (additional) mRNA vaccine dose, a Pfizer/BioNTech vaccine or a Moderna vaccine (100 mcg [0.5 mL]) should be administered as the 3<sup>rd</sup> dose at least 2 months after dose 2, regardless of type and timing of vaccine received as the 2<sup>nd</sup> dose.